Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01606735 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
A Phase 2 study of Inflammation Associated With Cataract Surgery, sponsored by ICON Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 2
- Study locations
NCT01606735 is a Phase 2 study of Inflammation Associated With Cataract Surgery that has completed, run by ICON Bioscience. The registered enrollment target is 172 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT01606735, a Phase 2 study of Inflammation Associated With Cataract Surgery, has completed, sponsored by ICON Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
Conditions Studied
Interventions
- DRUG IBI-10090
Study Locations (2)
California
- Inland Eye Specialists - Hemet
- California Eye Professionals - Temecula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01606735
The ClinicalTrials.gov registry entry for NCT01606735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ICON Bioscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Inflammation Associated With Cataract Surgery appearing as the primary indexed condition, and to 1 intervention - of which IBI-10090 is the first listed.
NCT01606735 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01606735 about?
NCT01606735 is a clinical study titled "Efficacy and Safety of IBI-10090 in Ocular Surgery Patients". This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
What is the current status of trial NCT01606735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2012-04. Estimated completion is 2013-03.
What conditions does trial NCT01606735 study?
This clinical trial studies the following conditions: Inflammation Associated With Cataract Surgery.
What interventions are being tested in trial NCT01606735?
The interventions under investigation include: IBI-10090 (DRUG).
Who is sponsoring clinical trial NCT01606735?
This trial is sponsored by ICON Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01606735 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.